|
EP0007450A1
(de)
*
|
1978-07-07 |
1980-02-06 |
Ciba-Geigy Ag |
Azatetracyclische Carbonitrile, ihre Herstellung, pharmazeutische Präparate, die diese enthalten und deren Verwendung
|
|
EP0030916B1
(de)
*
|
1979-12-10 |
1984-08-29 |
Ciba-Geigy Ag |
Azatetracyclische Carbonitrile
|
|
FR2504140A1
(fr)
*
|
1981-04-16 |
1982-10-22 |
Centre Nat Rech Scient |
Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
|
|
EP0094668B1
(de)
*
|
1982-05-18 |
1987-07-08 |
F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft |
Pyrrolo(3,4-d)(2)benzazepin-Derivate
|
|
JPS62101941U
(en:Method)
*
|
1985-12-16 |
1987-06-29 |
|
|
|
IE62754B1
(en)
*
|
1988-08-26 |
1995-02-22 |
Akzo Nv |
Tetracyclic antidepressants
|
|
EP0569096A1
(en)
*
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
|
CN1046723C
(zh)
*
|
1993-04-06 |
1999-11-24 |
艾博特公司 |
四环化合物、含有它们的药物组合物及其用途
|
|
HK1008417A1
(en)
*
|
1994-03-02 |
1999-05-07 |
Merck Sharp & Dohme B.V. |
Sublingual or buccal pharmaceutical composition
|
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
|
IL123655A
(en)
*
|
1996-04-12 |
2001-03-19 |
Janssen Pharmaceutica Nv |
Substituted tetracyclic tetrahydrofuran derivatives and pharmaceutical compositions containing them
|
|
HUP0002106A3
(en)
*
|
1997-05-26 |
2001-11-28 |
Akzo Nobel Nv |
Aromatic sulfonates of trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pyrrole and pharmaceutical compositions containing it
|
|
HRP20020305A8
(en)
*
|
2002-04-10 |
2009-03-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
|
|
HRP20020441A2
(en)
*
|
2002-05-21 |
2003-12-31 |
Pliva D D |
1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
|
|
HRP20030160A2
(en)
*
|
2003-03-06 |
2005-04-30 |
Pliva-Istra�iva�ki institut d.o.o. |
1-thiadibenzoazulene derivatives and biological action thereof
|
|
WO2004100992A2
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
|
HRP20030885A2
(en)
*
|
2003-11-03 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
|
|
HRP20030953A2
(en)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
|
HRP20030954A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva D.D. |
USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
|
HRP20030957A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
|
HRP20030959A2
(en:Method)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
|
|
HRP20030956A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
|
|
HRP20030958A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
|
HRP20030955A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
|
HRP20040104A2
(en)
*
|
2004-01-30 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
|
|
KR20060110006A
(ko)
*
|
2004-02-13 |
2006-10-23 |
화이자 프로덕츠 인크. |
비전형 항정신병제와 코르티코트로핀 방출 인자 길항제의치료적 조합물
|
|
BRPI0510942A
(pt)
*
|
2004-05-11 |
2007-07-17 |
Pfizer Prod Inc |
combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
|
|
US20060084692A1
(en)
*
|
2004-10-15 |
2006-04-20 |
Pfizer Inc. |
Treatment of bipolar disorders and associated symptoms
|
|
US7872147B2
(en)
*
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
|
DK1710241T3
(da)
*
|
2005-04-07 |
2010-03-01 |
Organon Nv |
Intermediatforbindelser til fremstilling af trans-5-chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol
|
|
ES2318742T3
(es)
*
|
2005-04-07 |
2009-05-01 |
N.V. Organon |
Forma cristalina de maleato de asenapina.
|
|
US7741358B2
(en)
*
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
|
WO2007046554A1
(ja)
*
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
|
TW200817414A
(en)
*
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
|
US7750167B2
(en)
*
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
|
CA2667668A1
(en)
*
|
2006-10-06 |
2008-04-10 |
N.V. Organon |
Amorphous asenapine and processes for preparing same
|
|
US7875729B2
(en)
*
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
|
WO2008148515A1
(en)
*
|
2007-06-05 |
2008-12-11 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
|
JP5245428B2
(ja)
*
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
|
MX2010007404A
(es)
*
|
2008-01-04 |
2010-10-05 |
Organon Nv |
Procedimiento para la preparacion de asenapina y productos intermediarios utilizados en dicho procedimiento.
|
|
WO2009104080A2
(en)
|
2008-02-20 |
2009-08-27 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
|
JP2011526881A
(ja)
*
|
2008-06-25 |
2011-10-20 |
ファイザー・インク |
ジアリール化合物およびそれらの使用
|
|
EP2453870A2
(en)
|
2009-06-24 |
2012-05-23 |
MSD Oss B.V. |
Injectable formulations containing asenapine and method of treatment using same
|
|
AR077429A1
(es)
|
2009-07-29 |
2011-08-24 |
Organon Nv |
Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
|
|
CA2802990A1
(en)
|
2010-06-18 |
2011-12-22 |
Dr. Reddy's Laboratories Ltd. |
Asenapine maleate
|
|
JP5815702B2
(ja)
|
2010-07-29 |
2015-11-17 |
ラボラトリオス レスヴィ,エス.エル. |
アセナピンの新規な製造方法
|
|
EA027840B1
(ru)
|
2010-11-15 |
2017-09-29 |
Эйджинбайо, Инк. |
Производные пиридазина, композиции и способы лечения когнитивного нарушения
|
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
|
ES2575544T3
(es)
|
2010-12-24 |
2016-06-29 |
Medichem, S.A. |
Procedimientos para la preparación de 5-cloro-2-metil-2,3,3a,12b-tetrahidro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pirrol
|
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
|
EP2524919A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
|
EP2524921A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
|
ES2665843T3
(es)
|
2011-05-18 |
2018-04-27 |
Laboratorios Lesvi, S.L. |
Síntesis de una forma de maleato de asenapina monoclínica micronizada estable
|
|
WO2012156676A1
(en)
|
2011-05-18 |
2012-11-22 |
Laboratorios Lesvi S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
|
WO2013011461A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
|
WO2013080069A1
(en)
|
2011-11-28 |
2013-06-06 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine intermediate
|
|
CN103254201B
(zh)
*
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
|
WO2013190481A1
(en)
*
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
|
EP2919788A4
(en)
|
2012-11-14 |
2016-05-25 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
|
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
|
CN103113379A
(zh)
*
|
2013-03-12 |
2013-05-22 |
盛世泰科生物医药技术(苏州)有限公司 |
阿塞那平马来酸盐的合成工艺
|
|
CN103351393B
(zh)
*
|
2013-07-03 |
2016-04-06 |
华裕(无锡)制药有限公司 |
用于制备阿森那平之还原剂及阿森那平之制备方法
|
|
JP6883988B2
(ja)
|
2013-12-20 |
2021-06-09 |
エージンバイオ, インコーポレイテッド |
ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
|
|
CN103772400A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
|
CN103772401A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
|
EP3307245A1
(en)
|
2015-06-11 |
2018-04-18 |
Alrise Biosystems GmbH |
Process for the preparation of drug loaded microparticles
|
|
IL256354B
(en)
|
2015-06-19 |
2022-09-01 |
Agenebio Inc |
Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment
|
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
BR112019012821A2
(pt)
|
2016-12-19 |
2019-11-26 |
Agenebio Inc |
derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
|
|
PL3338768T3
(pl)
|
2016-12-20 |
2020-05-18 |
Lts Lohmann Therapie-Systeme Ag |
Transdermalny system terapeutyczny zawierający asenapinę
|
|
RU2764443C2
(ru)
|
2016-12-20 |
2022-01-17 |
Лтс Ломанн Терапи-Систем Аг |
Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
|
|
WO2019002204A1
(en)
|
2017-06-26 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
|
|
MX2020013927A
(es)
|
2018-06-19 |
2021-03-02 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
|
|
PL3810100T3
(pl)
|
2018-06-20 |
2025-05-12 |
Lts Lohmann Therapie-Systeme Ag |
Transdermalny system terapeutyczny zawierający asenapinę
|
|
CN118806732A
(zh)
|
2018-06-20 |
2024-10-22 |
罗曼治疗系统股份公司 |
含有阿塞那平的透皮治疗系统
|
|
CN110183457A
(zh)
*
|
2019-06-27 |
2019-08-30 |
浙江天顺药业有限公司 |
一种阿塞那平及其制备方法
|
|
CN112830931A
(zh)
|
2019-08-13 |
2021-05-25 |
浙江奥翔药业股份有限公司 |
制备阿塞那平的方法
|
|
US11679407B2
(en)
*
|
2020-06-26 |
2023-06-20 |
Intel Corporation |
Liquid metal thermal interface material application
|
|
WO2023006954A1
(en)
|
2021-07-30 |
2023-02-02 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Asenapine for use in cancer
|
|
AU2023324882A1
(en)
|
2022-08-19 |
2025-03-20 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|